Benzodiazepine Risk and Deprescribing for Anxiety | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Benzodiazepine Risk and Deprescribing in Anxiety Care [ Medical Education ](https://mdster.com/blog?category=medical-education) Benzodiazepine Risk and Deprescribing in Anxiety Care ======================================================= A patient-centered primary care approach to dependence, rebound anxiety, safer alternatives, and gradual tapering [ MDster Editorial Team ](https://mdster.com/about) · Aug 19, 2026 · 5 min read · 193 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Family Medicine ](https://mdster.com/blog?tag=family-medicine) [ Anxiety Disorders ](https://mdster.com/blog?tag=anxiety-disorders) [ Behavioral Health ](https://mdster.com/blog?tag=behavioral-health) [ Medication Safety ](https://mdster.com/blog?tag=medication-safety) [ Deprescribing ](https://mdster.com/blog?tag=deprescribing) ![Benzodiazepine Risk and Deprescribing in Anxiety Care](https://mdster.com/storage/blog/images/benzodiazepine-risk-and-deprescribing-in-anxiety-care.jpg) Share this article Share this post On this page 1. [ Why Long-Term Benzodiazepine Use Becomes Risky ](#why-long-term-benzodiazepine-use-becomes-risky) 2. [ Build a Shared Deprescribing Plan ](#build-a-shared-deprescribing-plan) 3. [ Tapering Principles That Prevent Harm ](#tapering-principles-that-prevent-harm) 4. [ Manage Rebound Anxiety Without Replacing One Sedative ](#manage-rebound-anxiety-without-replacing-one-sedative) 5. [ Know When Outpatient Tapering Is Unsafe ](#know-when-outpatient-tapering-is-unsafe) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) On this page 1. [ Why Long-Term Benzodiazepine Use Becomes Risky ](#why-long-term-benzodiazepine-use-becomes-risky) 2. [ Build a Shared Deprescribing Plan ](#build-a-shared-deprescribing-plan) 3. [ Tapering Principles That Prevent Harm ](#tapering-principles-that-prevent-harm) 4. [ Manage Rebound Anxiety Without Replacing One Sedative ](#manage-rebound-anxiety-without-replacing-one-sedative) 5. [ Know When Outpatient Tapering Is Unsafe ](#know-when-outpatient-tapering-is-unsafe) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) A patient taking alprazolam for panic disorder reports dizziness, palpitations, and escalating anxiety whenever a dose is late. The common mistake is to increase the prescription. The safer interpretation may be **interdose withdrawal**, especially after regular use of a short-acting benzodiazepine. For family physicians, deprescribing is not simply medication subtraction. Treat the underlying anxiety disorder while allowing neuroadaptation to reverse at a tolerable pace. Why Long-Term Benzodiazepine Use Becomes Risky ---------------------------------------------- Chronic enhancement of GABA-A signaling produces physiologic adaptation. Removing that effect too quickly creates a hyperexcitable state marked by anxiety, insomnia, tremor, autonomic symptoms, perceptual changes, and—at the severe end—delirium or seizures. Physical dependence can develop during prescribed use and is distinct from benzodiazepine use disorder, which requires impaired control or continued use despite harm. [\[1\]](#cite-1 "Reference [1]") RiskFamily Medicine implicationDependence and withdrawalNever abruptly stop regular long-term therapyFalls and cognitive effectsReassess aggressively in adults aged 65 years or olderRespiratory depressionIdentify opioids, alcohol, and other CNS depressantsSymptom overlapDo not mistake withdrawal for worsening panic or somatic illness Older adults have greater benzodiazepine sensitivity and reduced clearance of long-acting agents. The AGS Beers Criteria associates the entire class with cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in this population. [\[2\]](#cite-2 "Reference [2]") Concurrent opioid use raises overdose risk through additive CNS and respiratory depression. Review the PDMP, reconcile all sedating medications, ask directly about alcohol, and provide naloxone when benzodiazepines and opioids are co-prescribed. [\[3\]](#cite-3 "Reference [3]") Build a Shared Deprescribing Plan --------------------------------- Do not announce that the prescription is being taken away. Explain that the risk-benefit balance has changed, then invite the patient to help design the taper. Shared decision-making improves trust and allows the goal to be complete discontinuation or reduction to a safer dose. [\[1\]](#cite-1 "Reference [1]") Document: - The original indication and current functional benefit - Dose, duration, adherence pattern, and prior taper attempts - Falls, cognition, driving, substance use, and overdose risk - A written reduction schedule with planned follow-up - Symptoms that trigger a pause versus urgent evaluation - Treatment for GAD, panic disorder, phobia, or insomnia > **Clinical Pearl:** Anxiety that predictably appears after each dose reduction and improves when the taper pauses is more suggestive of withdrawal than failure of the underlying anxiety treatment. Tapering Principles That Prevent Harm ------------------------------------- Most tapers can occur in primary care, but there is no universal schedule. Let symptom burden, duration of use, dose, age, comorbidity, and prior withdrawal determine the pace. 1. **Never abruptly discontinue** a benzodiazepine in a patient likely to be physically dependent. 2. Start with a reduction of approximately **5% to 10% of the current dose every two to four weeks**. The pace should generally not exceed 25% every two weeks. 3. Use smaller, less frequent reductions for older adults, long-term or high-dose use, and patients with previous difficult withdrawal. 4. Assess symptoms after every reduction. Pause or slow the taper before adding another medication. 5. Expect the final reductions to be the hardest; a taper may require months or occasionally longer. [\[1\]](#cite-1 "Reference [1]") Switching to diazepam or another longer-acting agent is optional, not mandatory. Conversion estimates are imprecise, and longer-acting agents may accumulate in older adults or significant hepatic impairment. Avoid automatic conversion in these groups. [\[1\]](#cite-1 "Reference [1]") Manage Rebound Anxiety Without Replacing One Sedative ----------------------------------------------------- Withdrawal, rebound anxiety, recurrent panic, and somatic illness can look identical. Palpitations, chest discomfort, paresthesias, dizziness, nausea, and tremor still require an appropriate medical assessment; do not attribute every symptom to anxiety. Optimize alternatives before or during the taper: Clinical problemPreferred approachGADCBT plus an SSRI or SNRI; consider buspirone selectivelyPanic disorderCBT with interoceptive exposure plus an SSRI or SNRISpecific phobiaExposure-based psychotherapyCoexisting insomniaCBT-I and structured sleep interventions SSRIs and SNRIs can initially increase activation, so start conservatively and titrate gradually. Benzodiazepines are not recommended for routine long-term panic treatment or GAD outside short-term crisis use. [\[4\]](#cite-4 "Reference [4]") No adjunctive drug reliably eliminates benzodiazepine withdrawal. Prioritize CBT, reassurance, sleep regularity, exercise, and a slower taper. Do not substitute a Z-drug or stack sedating medications with similar fall, cognitive, or misuse risks. [\[1\]](#cite-1 "Reference [1]") Know When Outpatient Tapering Is Unsafe --------------------------------------- Arrange higher-level or inpatient management for severe or complicated withdrawal, delirium, seizures, unstable seizure disorders, imminent overdose risk, serious medication interactions, suicidality, or recurrent falls that cannot be rapidly mitigated. A history of complicated withdrawal should lower your threshold for specialist involvement. [\[1\]](#cite-1 "Reference [1]") Key Takeaways ------------- - Physical dependence is expected with regular exposure; it does not automatically mean addiction. - Abrupt cessation can cause life-threatening withdrawal. - Begin with small reductions and individualize every subsequent step. - Treat GAD, panic, phobias, insomnia, and somatic overlap in parallel. - Use shared planning, frequent follow-up, and pauses rather than forcing a fixed calendar. - Reassess older adults and patients taking opioids with particular urgency. Conclusion ---------- As of August 2026, best practice remains a slow, collaborative taper supported by evidence-based anxiety treatment. Deprescribe the benzodiazepine, but never deprescribe the therapeutic relationship. Frequently Asked Questions ---------------------------- ### How quickly should a long-term benzodiazepine be tapered? A common starting pace is a 5% to 10% reduction every two to four weeks, adjusted to symptoms. Slower reductions may be necessary near discontinuation. [\[1\]](#cite-1 "Reference [1]") ### Does physical dependence mean the patient has an addiction? No. Dependence is a physiologic adaptation. Benzodiazepine use disorder additionally involves features such as impaired control and continued use despite harm. [\[1\]](#cite-1 "Reference [1]") ### Should every patient be switched to diazepam before tapering? No. Longer-acting conversion is optional and patient-specific. It may be inappropriate in older adults, significant hepatic impairment, or complex polypharmacy. [\[1\]](#cite-1 "Reference [1]") ### What should I do if anxiety worsens during the taper? Assess for medical causes and determine whether symptoms track dose reductions. Pause or slow the taper, reinforce CBT, and optimize non-benzodiazepine treatment for the underlying disorder. [\[1\]](#cite-1 "Reference [1]") References (8) ------------------ 1. 1. [ downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/benzodiazepine-tapering-2025/bzd-tapering-document---final-approved-version-for-distribution-02-28-25.pdf?sfvrsn=5bdf9c81\_1 ](https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/benzodiazepine-tapering-2025/bzd-tapering-document---final-approved-version-for-distribution-02-28-25.pdf?sfvrsn=5bdf9c81_1) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ pmc.ncbi.nlm.nih.gov/articles/PMC12478568 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC12478568/) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm ](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ www.nice.org.uk/guidance/cg113/chapter/Recommendations ](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ Joint Clinical Practice Guideline on Benzodiazepine Tapering, ASAM, 2025 ](https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering) 6. 6. [ Benzodiazepine Tapering: Joint Guidelines From ASAM, American Family Physician, 2026 ](https://www.aafp.org/afp/2026/0600/practice-guidelines-benzodiazepine-tapering) 7. 7. [ FDA Drug Safety Communication: Updated Boxed Warning for Benzodiazepines ](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class) 8. 8. [ American Geriatrics Society 2023 Updated AGS Beers Criteria ](https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372) Next Stay consistent in Family Medicine prep with a guided pathway --------------------------------------------------------------- - Broad coverage without the overwhelm - Short daily sessions that compound - See your progress and focus on weak areas [ Start practicing ](https://mdster.com/user/dashboard) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Family Medicine ](https://mdster.com/blog?tag=family-medicine) [ # Anxiety Disorders ](https://mdster.com/blog?tag=anxiety-disorders) [ # Behavioral Health ](https://mdster.com/blog?tag=behavioral-health) [ # Medication Safety ](https://mdster.com/blog?tag=medication-safety) [ # Deprescribing ](https://mdster.com/blog?tag=deprescribing) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Applying Guidelines to Individuals in Obstetrics and Gynecology 6 min read Oct 03, 2026 ](https://mdster.com/blog/applying-guidelines-to-individuals-in-obstetrics-and-gynecology) [### Breastfeeding Nipple Pain: Trauma, Thrush, or Dermatitis? 6 min read Oct 02, 2026 ](https://mdster.com/blog/breastfeeding-nipple-pain-trauma-thrush-or-dermatitis) [### Nephrotic Syndrome: Managing Edema, Clot Risk, and Infection 5 min read Oct 01, 2026 ](https://mdster.com/blog/nephrotic-syndrome-managing-edema-clot-risk-and-infection) Related Posts ------------- [ ![Applying Guidelines to Individuals in Obstetrics and Gynecology](https://mdster.com/storage/blog/images/applying-guidelines-to-individuals-in-obstetrics-and-gynecology.png) Medical Education ### Applying Guidelines to Individuals in Obstetrics and Gynecology Learn when an OB-GYN guideline fits the patient in front of you, how to reconcile conflicting recommendations, and how to make preference-sensitive decisions. 6 min read 0 comments ](https://mdster.com/blog/applying-guidelines-to-individuals-in-obstetrics-and-gynecology) [ Medical Education ### Breastfeeding Nipple Pain: Trauma, Thrush, or Dermatitis? A burning nipple is not automatically thrush. Learn to distinguish latch trauma, dermatitis, candidiasis, and vasospasm—and recognize when a breastfeeding dyad needs referral. 6 min read 0 comments ](https://mdster.com/blog/breastfeeding-nipple-pain-trauma-thrush-or-dermatitis) [ ![Nephrotic Syndrome: Managing Edema, Clot Risk, and Infection](https://mdster.com/storage/blog/images/nephrotic-syndrome-managing-edema-clot-risk-and-infection.png) Medical Education ### Nephrotic Syndrome: Managing Edema, Clot Risk, and Infection Nephrotic-range proteinuria is only the beginning. Learn how to assess edema, recognize thrombosis and infection, and avoid common management pitfalls. 5 min read 0 comments ](https://mdster.com/blog/nephrotic-syndrome-managing-edema-clot-risk-and-infection) [ ![Neurocutaneous Syndromes in Pediatrics: Three Screening Priorities](https://mdster.com/storage/blog/images/neurocutaneous-syndromes-in-pediatrics-three-screening-priorities.png) Medical Education ### Neurocutaneous Syndromes in Pediatrics: Three Screening Priorities A practical pediatric approach to NF1 surveillance, Sturge–Weber vascular malformations, and tuberous sclerosis–associated seizures, with the pitfalls that matter on rounds. 6 min read 0 comments ](https://mdster.com/blog/neurocutaneous-syndromes-in-pediatrics-three-screening-priorities) [ ![ECT Physiology and Anesthetic Technique: Airway, Seizure, Surge](https://mdster.com/storage/blog/images/ect-physiology-and-anesthetic-technique-airway-seizure-surge.png) Medical Education ### ECT Physiology and Anesthetic Technique: Airway, Seizure, Surge ECT lasts minutes, but airway failure, an inadequate seizure, or a cardiovascular surge can change the case. Learn how to plan the anesthetic around all three. 6 min read 0 comments ](https://mdster.com/blog/ect-physiology-and-anesthetic-technique-airway-seizure-surge) [ ![EMS Documentation and Medico-Legal Oversight: Handoffs and Refusals](https://mdster.com/storage/blog/images/ems-documentation-and-medico-legal-oversight-handoffs-and-refusals.png) Medical Education ### EMS Documentation and Medico-Legal Oversight: Handoffs and Refusals Follow a patient from field assessment to ED handoff, safety-event review, or informed refusal—and learn what EMS documentation must preserve at each decision point. 6 min read 0 comments ](https://mdster.com/blog/ems-documentation-and-medico-legal-oversight-handoffs-and-refusals) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ Download on the App Store ](https://apps.apple.com/app/id6759168258) [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Curriculum](https://mdster.com/curriculum) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) [ ](https://apps.apple.com/app/id6759168258) [ ](https://play.google.com/store/apps/details?id=com.mdster.app) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept